Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 17.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,078 shares of the medical research company’s stock after acquiring an additional 1,176 shares during the period. Sequoia Financial Advisors LLC’s holdings in Edwards Lifesciences were worth $598,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. Wellington Management Group LLP raised its holdings in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares in the last quarter. Jennison Associates LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $555,939,000. Assenagon Asset Management S.A. lifted its holdings in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after buying an additional 3,506,886 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $213,844,000. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Edwards Lifesciences by 239.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after acquiring an additional 2,606,950 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 2.0 %

Shares of EW stock opened at $70.67 on Tuesday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm’s 50-day simple moving average is $71.68 and its 200-day simple moving average is $70.34. The firm has a market cap of $41.55 billion, a P/E ratio of 10.14, a PEG ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,189,770.56. This represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 51,303 shares of company stock worth $3,715,776 over the last three months. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have commented on EW. Morgan Stanley raised their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Citigroup upped their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Piper Sandler lifted their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.